The AR-V7 gene, associated with resistance to AR-targeting agents in patients with mCRPC, was only detected in metastatic cancer patients and displayed twice the detection rate, with an expression level that was 10 times higher for the CTC-μChip than for the AdnaTest. The gene discussed is AR; the disease is metastatic malignant neoplasm.